USPTO 2015–2025 USPTO PatentsView US Corporation

Parenteral Technologies, Llc

USPTO PatentsView assignee record - 11 granted patents across 3 technology areas, active 2015–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).

11
Total patents granted
3
CPC technology areas
16.4
Avg claims per patent
-17%
5-year filing velocity

The verdict

Parenteral holds 11 US patents across 3 technology areas, rank #24,987 of 50,000 tracked assignees.

#24,987
of 50,000 US assignees by volume
Top 71%
by Innovation Score (29.0/100)
16.4
avg claims per patent
-17%
filing velocity, last 5 yrs

Portfolio overview

Parenteral Technologies, Llc has been granted 11 US utility patents between 2015 and 2022, placing Parenteral Technologies, Llc at rank #24,987 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.4 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a US Corporation, Parenteral Technologies, Llc is one of the more focused assignees in the PatentsView dataset. By volume, Parenteral sits between Packaging Technologies & Inspection, Llc (11 patents, rank #24,983) and Peptidream Inc. (11 patents, rank #24,991) - the closest US assignees by grant volume. The composite Innovation Score of 29.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 5 grants, compared with 6 in the 2015–2019 window, a -17% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Parenteral Technologies, Llc's 16.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Parenteral Technologies, Llc against peers pursuing similar technology classes.

Who files at Parenteral's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Parenteral holds 11 patents at rank #24,987, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Parenteral's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

29 Top 71% higher than 29% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). This entry sits in this band. 30–40: 15,294 US assignees (31%). Above this entry. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 2015201620172018202020212022 2
USPTO utility patent grants by year · 2015–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Parenteral Technologies, Llc patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 1 9.1%
2016 2 18.2%
2017 2 18.2%
2018 1 9.1%
2020 2 18.2%
2021 1 9.1%
2022 2 18.2%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#24,987

Across all tracked assignees

Innovation Score

29.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Parenteral Technologies, Llc hold?
Parenteral Technologies, Llc holds 11 US granted patents filed between 2015 and 2022, spanning 3 technology areas.
What is Parenteral Technologies, Llc's Innovation Score?
Parenteral Technologies, Llc has an Innovation Score of 29.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Parenteral Technologies, Llc focus on?
Parenteral Technologies, Llc's top technology area is A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR) with 10 patents. The company has filed patents in 3 CPC subclasses total.
Is Parenteral Technologies, Llc's patent filing rate increasing or decreasing?
Parenteral Technologies, Llc's recent filing velocity is -17% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Parenteral Technologies, Llc's patents?
Parenteral Technologies, Llc's patents average 16.4 claims each. This falls within the standard range, providing solid legal coverage.
How is the Parenteral Technologies, Llc patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Parenteral's 11 grants land it in the top 71% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Parenteral ranks #24,987 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61M - see who else leads that technology area. A61M leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.